{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:04:34Z","timestamp":1790640274469,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In treating Chronic Hepatitis B (CHB), tenofovir disoproxil fumarate (TDF) carries risks like renal toxicity and reduced bone mineral density (BMD). TAF, the next-generation prodrug of TFV, is more stable in plasma than TDF, requires a significantly lower dose (25\u00a0mg vs. 300\u00a0mg), and results in approximately 90% lower plasma TFV levels, contributing to a more favorable renal and bone safety profile. This study aimed to evaluate the efficacy and safety of tenofovir alafenamide fumarate (TAF) compared to TDF in CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a search on PubMed, Google Scholar, and the Cochrane Library. Only four RCTs that studied the comparison of efficacy and safety of TAF and TDF in treating CHB were included. The Primary outcome of interest was the proportion of patients with Hepatitis B virus (HBV) DNA below 15\u201329 IU\/ml as all the RCT\u2019s included in this study report the same HBV DNA levels. We used a random-effects model to calculate the Risk Ratio (RR) and Mean Difference (MD) with 95% CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta-analysis includes four eligible RCTs including 1,960 total patients. The comparison between TAF and TDF groups regarding HBV DNA level revealed no significant difference (RR\u2009=\u20091.00, 95% CI\u2009=\u20090.96 to 1.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.82). Pooled data showed beneficial effects of TAF compared with TDF for ALT Normalization (RR\u2009=\u20091.38; 95% CI\u2009=\u20091.16 TO 1.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002), Hip BMD (MD\u2009=\u20091.44, 95% CI\u2009=\u20090.98 to 1.91; P \u2039 0.00001), Spine BMD (MD\u2009=\u20091.93, 95% CI\u2009=\u20091.42 to 2.44; P \u2039 0.00001), serum creatinine concentration (MD= -0.02, 95% CI=-0.03 to -0.01; P \u2039 0.00001) and eGFR (MD\u2009=\u20093.55, 95% CI\u2009=\u20092.97 to 4.14; P \u2039 0.00001). However, the TAF group showed a significantly greater proportion of patients (46\/1080 vs. 5\/662) with LDL levels\u2009&gt;\u2009190 or 300\u00a0mg\/dl than the TDF group (RR\u2009=\u20094.95, 95% CI\u2009=\u20091.21 to 20.29;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The TAF demonstrated improved BMD and renal function compared to TDF. There was no significant difference between TAF and TDF in achieving viral suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>This was a systematic review and meta-analysis not a clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis is registered at PROSPERO (CRD42023456006).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13974-4","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:47:17Z","timestamp":1783331237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil in chronic hepatitis b: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4552-913X","authenticated-orcid":false,"given":"Marrium Sultan","family":"Dar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6173-7742","authenticated-orcid":false,"given":"Haziq","family":"Ovais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-8328","authenticated-orcid":false,"given":"Aimen Waqar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1559-5604","authenticated-orcid":false,"given":"Samra","family":"Ishaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5071-3404","authenticated-orcid":false,"given":"Yusra Muhammad","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5009-842X","authenticated-orcid":false,"given":"Syeda Dua","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9841-7830","authenticated-orcid":false,"given":"Muhammad","family":"Affan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-5171","authenticated-orcid":false,"given":"Zuhaa","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6761-8878","authenticated-orcid":false,"given":"Fabiha","family":"Athar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8328","authenticated-orcid":false,"given":"Tooba","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3991-9152","authenticated-orcid":false,"given":"Jawad","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9518-1659","authenticated-orcid":false,"given":"Saqib","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-8109","authenticated-orcid":false,"given":"Noor","family":"ul Ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Surani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-2030","authenticated-orcid":false,"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4608-5321","authenticated-orcid":false,"given":"Khabab Abbasher Hussien Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"13","key":"13974_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","volume":"6","author":"M Jefferies","year":"2018","unstructured":"Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin cases. 2018;6(13):589.","journal-title":"World J Clin cases"},{"key":"13974_CR2","unstructured":"Hepatitis B, September | WHO. Accessed 7th 2023 am. https:\/\/www.who.int\/news-room\/factsheets\/detail."},{"issue":"2","key":"13974_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3350\/kjhep.2011.17.2.87","volume":"17","author":"SY Kwon","year":"2011","unstructured":"Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17(2):87.","journal-title":"Korean J Hepatol"},{"issue":"4","key":"13974_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cld.2016.06.006","volume":"20","author":"NP Nelson","year":"2016","unstructured":"Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20(4):607\u201328.","journal-title":"Clin Liver Dis"},{"key":"13974_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/liv.14359","volume":"40","author":"ML Shiffman","year":"2020","unstructured":"Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int. 2020;40:22\u20136.","journal-title":"Liver Int"},{"issue":"5","key":"13974_CR6","first-page":"314","volume":"99","author":"T Wilkins","year":"2019","unstructured":"Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment. Am Family Phys. 2019;99(5):314\u201323.","journal-title":"Am Family Phys"},{"issue":"3","key":"13974_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"13974_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/v12090998","volume":"12","author":"GS Duraisamy","year":"2020","unstructured":"Duraisamy GS, Bhosale D, Lipensk\u00e1 I, Huvarova I, R\u016f\u017eek D, Windisch MP, Miller AD. Advanced therapeutics, vaccinations, and precision medicine in the treatment and management of chronic hepatitis b viral infections; where are we and where are we going? Viruses. 2020;12(9):998.","journal-title":"Viruses"},{"issue":"2","key":"13974_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/CMR.00046-19","volume":"33","author":"MH Nguyen","year":"2020","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2):10\u2013128.","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"13974_CR10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1128\/AAC.00138-06","volume":"50","author":"IVWE Delaney","year":"2006","unstructured":"Delaney IVWE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50(7):2471\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"13974_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jhep.2016.08.008","volume":"66","author":"S Fung","year":"2017","unstructured":"Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)\/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017;66(1):11\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"13974_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","volume":"67","author":"PE Sax","year":"2014","unstructured":"Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. JAIDS J Acquir Immune Defic Syndr. 2014;67(1):52\u20138.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"3","key":"13974_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, Chuang WL, Janssen HLA, Fung S, Izumi N, Abdurakhmanov D. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119(3):486\u201396.","journal-title":"Am J Gastroenterol"},{"issue":"suppl8","key":"13974_CR14","doi-asserted-by":"publisher","first-page":"S792","DOI":"10.1093\/infdis\/jix135","volume":"216","author":"M Buti","year":"2017","unstructured":"Buti M, Riveiro-Barciela M, Esteban R. Tenofovir alafenamide fumarate: a new tenofovir prodrug for the treatment of chronic hepatitis B infection. J Infect Dis. 2017;216(suppl8):S792\u20136.","journal-title":"J Infect Dis"},{"issue":"6","key":"13974_CR15","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.00128-15","volume":"59","author":"E Murakami","year":"2015","unstructured":"Murakami E, Wang T, Park Y, Hao J, Lepist EI, Babusis D, Ray AS. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59(6):3563\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"13974_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. lancet Gastroenterol Hepatol. 2016;1(3):185\u201395.","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"5","key":"13974_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. lancet Gastroenterol Hepatol. 2020;5(5):441\u201353.","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"2","key":"13974_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","volume":"20","author":"KS Byun","year":"2022","unstructured":"Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, Yoo BC, Kwon SY, Gwak GY, Lim YS. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20(2):427\u201337.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"13974_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore MD). 2016;63(1):261.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"13974_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167\u201385.","journal-title":"J Hepatol"},{"key":"13974_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Intl. 2012;6:531\u201361.","journal-title":"Hep Intl"},{"issue":"2","key":"13974_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, Buti M, Janssen HL, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"4","key":"13974_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"key":"13974_CR24","doi-asserted-by":"crossref","first-page":"A313","DOI":"10.1002\/hep.27486","volume":"60","author":"P Marcellin","year":"2014","unstructured":"Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, Kaita KD, Kotzev IA, Tsai N, Flaherty JF, Schall RE. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials: 229. Hepatology. 2014;60:A313\u20134.","journal-title":"Hepatology"},{"issue":"4","key":"13974_CR25","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1053\/j.gastro.2013.12.028","volume":"146","author":"S Fung","year":"2014","unstructured":"Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146(4):980\u20138.","journal-title":"Gastroenterology"},{"issue":"11\u201312","key":"13974_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, Chuang WL, Janssen HLA, Fung SK, Izumi N, Jablkowski MS. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60(11\u201312):1573\u201386.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"13974_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.24871\/2332022217-226","volume":"23","author":"RC Saputra","year":"2022","unstructured":"Saputra RC, Hidayat N. Evaluation Effect of Tenofovir Alafenamide (TAF) in Long-Term Therapy for Chronic Hepatitis B: A Systematic Review. Indonesian J Gastroenterol Hepatol Dig Endoscopy. 2022;23(3):216\u201325.","journal-title":"Indonesian J Gastroenterol Hepatol Dig Endoscopy"},{"issue":"11","key":"13974_CR28","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jgh.14686","volume":"34","author":"S Kaneko","year":"2019","unstructured":"Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019;34(11):2004\u201310.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"13974_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jvh.13053","volume":"26","author":"TL Fong","year":"2019","unstructured":"Fong TL, Lee BT, Tien A, Chang M, Lim C, Ahn A, Bae HS. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepatitis. 2019;26(5):561\u20137.","journal-title":"J Viral Hepatitis"},{"issue":"9987","key":"13974_CR30","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606\u201315.","journal-title":"Lancet"},{"key":"13974_CR31","doi-asserted-by":"publisher","first-page":"1076739","DOI":"10.3389\/fendo.2023.1076739","volume":"14","author":"J Soldado-Folgado","year":"2023","unstructured":"Soldado-Folgado J, Rins-Lozano O, Arrieta-Aldea I, Gonz\u00e1le-Mena A, Ca\u00f1as-Ruano E, Knobel H, Garcia-Giralt N, G\u00fcerri-Fern\u00e1ndez R. Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study. Front Endocrinol. 2023;14:1076739.","journal-title":"Front Endocrinol"},{"issue":"5","key":"13974_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"AM Hall","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773\u201380.","journal-title":"Am J Kidney Dis"},{"key":"13974_CR33","doi-asserted-by":"crossref","unstructured":"Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M. Tenofovir nephrotoxicity: 2011 update. AIDS research and treatment. 2011;2011.","DOI":"10.1155\/2011\/354908"},{"issue":"6","key":"13974_CR34","doi-asserted-by":"publisher","first-page":"e38377","DOI":"10.1371\/journal.pone.0038377","volume":"7","author":"H Haskelberg","year":"2012","unstructured":"Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A, STEAL Study Group. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE. 2012;7(6):e38377.","journal-title":"PLoS ONE"},{"issue":"1","key":"13974_CR35","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12876-023-03027-4","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23(1):384.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"13974_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403\u20138.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"13974_CR37","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781.","journal-title":"AIDS"},{"key":"13974_CR38","unstructured":"Hwang EG, Jung E, Yoo JJ, Kim SG, Kim YS. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hep Intl. 2023 Apr;26:1\u20130."},{"issue":"6","key":"13974_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"AA Shaheen","year":"2017","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos (t) ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46(6):599\u2013604.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13974-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:40:49Z","timestamp":1790638849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13974"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13974-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1734"}}